用于评估囊性纤维化跨膜传导调节因子（CFTR）离子通道活性的鼻电位差测量
Nasal potential difference measurements to assess CFTR ion channel activity.
作者信息
Rowe Steven M, Clancy John Paul, Wilschanski Michael
机构信息
Department of Medicine, University of Alabama, Birmingham, AL 35294-0006, USA.
出版信息
Methods Mol Biol. 2011;741:69-86. doi: 10.1007/978-1-61779-117-8_6.
Abstract
The Nasal potential difference measurement is used to measure the voltage across the nasal epithelium, which results from transepithelial ion transport and reflects in part CFTR function. The electrophysiologic abnormality in cystic fibrosis was first described 30 years ago and correlates with features of the CF phenotype. NPD measurement is an important in vivo research and diagnostic tool, and is used to assess the efficacy of new treatments such as gene therapy and ion transport modulators. This chapter will elaborate on the electrophysiological principles behind the test, the equipment required, the methods, and the analysis of the data.
摘要
鼻电位差测量用于测量鼻上皮细胞两端的电压，该电压由跨上皮离子转运产生，部分反映了囊性纤维化跨膜传导调节因子（CFTR）的功能。囊性纤维化的电生理异常在30年前首次被描述，与CF表型的特征相关。鼻电位差测量是一种重要的体内研究和诊断工具，用于评估基因治疗和离子转运调节剂等新治疗方法的疗效。本章将详细阐述该测试背后的电生理原理、所需设备、方法以及数据分析。
相似文献
1
Nasal potential difference measurements to assess CFTR ion channel activity.
Methods Mol Biol. 2011;741:69-86. doi: 10.1007/978-1-61779-117-8_6.
2
Basic protocol for transepithelial nasal potential difference measurements.
J Cyst Fibros. 2004 Aug;3 Suppl 2:151-5. doi: 10.1016/j.jcf.2004.05.032.
3
Transepithelial nasal potential difference (NPD) measurements in cystic fibrosis (CF).
Med Wieku Rozwoj. 2013 Jan-Mar;17(1):13-7.
4
In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis.
Hum Gene Ther. 1995 Apr;6(4):445-55. doi: 10.1089/hum.1995.6.4-445.
5
The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening.
BMC Pediatr. 2006 Oct 3;6:25. doi: 10.1186/1471-2431-6-25.
6
Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis.
PLoS One. 2013;8(3):e57617. doi: 10.1371/journal.pone.0057617. Epub 2013 Mar 6.
7
Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD).
J Vis Exp. 2018 Sep 13(139):57006. doi: 10.3791/57006.
8
A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.
N Engl J Med. 1995 Sep 28;333(13):823-31. doi: 10.1056/NEJM199509283331302.
9
Characterization of nasal potential difference in cftr knockout and F508del-CFTR mice.
PLoS One. 2013;8(3):e57317. doi: 10.1371/journal.pone.0057317. Epub 2013 Mar 7.
10
Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis?
Ann Am Thorac Soc. 2014 May;11(4):562-70. doi: 10.1513/AnnalsATS.201311-412OC.
引用本文的文献
1
Phytochemical-mediated efferocytosis and autophagy in inflammation control.
Cell Death Discov. 2024 Dec 18;10(1):493. doi: 10.1038/s41420-024-02254-2.
2
Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241297877. doi: 10.1177/17534666241297877.
3
Phenotypic Evaluation of Rare Cystic Fibrosis Transmembrane Conductance Regulator Mutation Combinations in People with Cystic Fibrosis in Queensland, Australia.
J Clin Med. 2024 Oct 18;13(20):6210. doi: 10.3390/jcm13206210.
4
Personalized CFTR Modulator Therapy for and Homozygous Patients with Cystic Fibrosis.
Int J Mol Sci. 2023 Aug 2;24(15):12365. doi: 10.3390/ijms241512365.
5
Differential effects of ELX/TEZ/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G.
Front Pharmacol. 2023 Mar 27;14:1153656. doi: 10.3389/fphar.2023.1153656. eCollection 2023.
6
The Cystic Fibrosis Upper and Lower Airway Metagenome.
Microbiol Spectr. 2023 Mar 9;11(2):e0363322. doi: 10.1128/spectrum.03633-22.
7
Diagnostic agreement among experts assessing adults presenting with possible cystic fibrosis: need for improvement and implications for patient care.
ERJ Open Res. 2022 Dec 12;8(4). doi: 10.1183/23120541.00227-2022. eCollection 2022 Oct.
8
Vegetable glycerin e-cigarette aerosols cause airway inflammation and ion channel dysfunction.
Front Pharmacol. 2022 Sep 26;13:1012723. doi: 10.3389/fphar.2022.1012723. eCollection 2022.
9
Assays of CFTR Function In Vitro, Ex Vivo and In Vivo.
Int J Mol Sci. 2022 Jan 27;23(3):1437. doi: 10.3390/ijms23031437.
10
Assessment of Lentiviral Vector Mediated CFTR Correction in Mice Using an Improved Rapid Nasal Potential Difference Measurement Protocol.
Front Pharmacol. 2021 Jul 27;12:714452. doi: 10.3389/fphar.2021.714452. eCollection 2021.
本文引用的文献
1
Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.
J Pediatr. 2008 Aug;153(2):S4-S14. doi: 10.1016/j.jpeds.2008.05.005.
2
Reproducibility of nasal potential difference measurements in cystic fibrosis.
Chest. 2007 Oct;132(4):1219-26. doi: 10.1378/chest.06-2975. Epub 2007 Sep 21.
3
Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.
Proc Am Thorac Soc. 2007 Aug 1;4(4):387-98. doi: 10.1513/pats.200703-043BR.
4
In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
BMC Med. 2007 Mar 29;5:5. doi: 10.1186/1741-7015-5-5.
5
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
Am J Respir Cell Mol Biol. 2007 Jul;37(1):57-66. doi: 10.1165/rcmb.2006-0173OC. Epub 2007 Mar 8.
6
Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials.
Am J Respir Crit Care Med. 2006 Oct 1;174(7):787-94. doi: 10.1164/rccm.200509-1377OC. Epub 2006 Jul 13.
7
Cystic fibrosis: terminology and diagnostic algorithms.
Thorax. 2006 Jul;61(7):627-35. doi: 10.1136/thx.2005.043539. Epub 2005 Dec 29.
8
Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners.
Pharmacol Ther. 2005 Nov;108(2):208-23. doi: 10.1016/j.pharmthera.2005.04.004. Epub 2005 Jun 2.
9
Cystic fibrosis.
N Engl J Med. 2005 May 12;352(19):1992-2001. doi: 10.1056/NEJMra043184.
10
Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.
Hum Gene Ther. 2004 Dec;15(12):1255-69. doi: 10.1089/hum.2004.15.1255.
Zotero 插件